Clinical Trials Browser

Phase 2 × OTHER × Nasopharyngeal Carcinoma × Clear all

NCT06093061 2026-04-14

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07325539 2026-04-13

LIGHT

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06532279 2026-04-03

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT06788002 2026-04-02

Light

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07101744 2026-01-23

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT03267498 2026-01-12

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

40 enrolled 14 charts

Nasopharyngeal Carcinoma

NCT04227509 2025-12-31

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05340270 2025-12-11

NeoTurbo

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT07277764 2025-12-11

REDEFINE

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04925544 2025-10-21

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07110558 2025-08-07

PUPA

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07085988 2025-07-25

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07064902 2025-07-18

Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT03984357 2025-07-17

PLATINUM

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT07067268 2025-07-16

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT04833257 2025-07-08

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05508347 2025-04-09

Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06605131 2025-03-20

GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT04223024 2025-03-05

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT03930498 2025-01-28

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06781112 2025-01-17

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06349889 2025-01-15

Adebrelimab and Chemoradiotherapy in High-risk LANPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06472713 2025-01-13

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06657690 2025-01-10

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT06733948 2024-12-13

ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Nasopharyngeal Carcinoma, Recurrence

NCT06680115 2024-11-08

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06323239 2024-08-20

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT05193617 2024-07-23

Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT06301165 2024-07-08

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06455410 2024-06-25

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma